CHAPTER 1: INTRODUCTION
1.1. Report Description
1.2. Key Market Segments
1.3. Key Benefits
1.4. Research Methodology
1.4.1. Primary Research
1.4.2. Secondary Research
1.4.3. Analyst Tools and Models
CHAPTER 2: EXECUTIVE SUMMARY
2.1. CXO Perspective
CHAPTER 3: MARKET LANDSCAPE
3.1. Market Definition and Scope
3.2. Key Findings
3.2.1. Top Investment Pockets
3.2.2. Top Winning Strategies
3.3. Porter's Five Forces Analysis
3.3.1. Bargaining Power of Suppliers
3.3.2. Threat of New Entrants
3.3.3. Threat of Substitutes
3.3.4. Competitive Rivalry
3.3.5. Bargaining Power among Buyers
3.4. Market Dynamics
3.4.1. Drivers
3.4.2. Restraints
3.4.3. Opportunities
CHAPTER 4: VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY VECTOR TYPE
4.1. Market Overview
4.1.1 Market Size and Forecast, By Vector Type
4.2. Adenovirus
4.2.1. Key Market Trends, Growth Factors and Opportunities
4.2.2. Market Size and Forecast, By Region
4.2.3. Market Share Analysis, By Country
4.3. Retrovirus
4.3.1. Key Market Trends, Growth Factors and Opportunities
4.3.2. Market Size and Forecast, By Region
4.3.3. Market Share Analysis, By Country
4.4. Adeno-Associated Virus (AAV)
4.4.1. Key Market Trends, Growth Factors and Opportunities
4.4.2. Market Size and Forecast, By Region
4.4.3. Market Share Analysis, By Country
4.5. Lentivirus
4.5.1. Key Market Trends, Growth Factors and Opportunities
4.5.2. Market Size and Forecast, By Region
4.5.3. Market Share Analysis, By Country
4.6. Plasmids
4.6.1. Key Market Trends, Growth Factors and Opportunities
4.6.2. Market Size and Forecast, By Region
4.6.3. Market Share Analysis, By Country
4.7. Others
4.7.1. Key Market Trends, Growth Factors and Opportunities
4.7.2. Market Size and Forecast, By Region
4.7.3. Market Share Analysis, By Country
CHAPTER 5: VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY WORKFLOW
5.1. Market Overview
5.1.1 Market Size and Forecast, By Workflow
5.2. Upstream Manufacturing
5.2.1. Key Market Trends, Growth Factors and Opportunities
5.2.2. Market Size and Forecast, By Region
5.2.3. Market Share Analysis, By Country
5.3. Downstream Manufacturing
5.3.1. Key Market Trends, Growth Factors and Opportunities
5.3.2. Market Size and Forecast, By Region
5.3.3. Market Share Analysis, By Country
CHAPTER 6: VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY APPLICATION
6.1. Market Overview
6.1.1 Market Size and Forecast, By Application
6.2. Antisense RNAi Therapy
6.2.1. Key Market Trends, Growth Factors and Opportunities
6.2.2. Market Size and Forecast, By Region
6.2.3. Market Share Analysis, By Country
6.3. Antisense RNAi Therapy
6.3.1. Key Market Trends, Growth Factors and Opportunities
6.3.2. Market Size and Forecast, By Region
6.3.3. Market Share Analysis, By Country
6.4. Cell Therapy
6.4.1. Key Market Trends, Growth Factors and Opportunities
6.4.2. Market Size and Forecast, By Region
6.4.3. Market Share Analysis, By Country
6.5. Vaccinology
6.5.1. Key Market Trends, Growth Factors and Opportunities
6.5.2. Market Size and Forecast, By Region
6.5.3. Market Share Analysis, By Country
6.6. Research Applications
6.6.1. Key Market Trends, Growth Factors and Opportunities
6.6.2. Market Size and Forecast, By Region
6.6.3. Market Share Analysis, By Country
CHAPTER 7: VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY END USER
7.1. Market Overview
7.1.1 Market Size and Forecast, By End User
7.2. Pharmaceutical Biopharmaceutical Companies
7.2.1. Key Market Trends, Growth Factors and Opportunities
7.2.2. Market Size and Forecast, By Region
7.2.3. Market Share Analysis, By Country
7.3. Research Institutes
7.3.1. Key Market Trends, Growth Factors and Opportunities
7.3.2. Market Size and Forecast, By Region
7.3.3. Market Share Analysis, By Country
CHAPTER 8: VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY REGION
8.1. Market Overview
8.1.1 Market Size and Forecast, By Region
8.2. North America
8.2.1. Key Market Trends and Opportunities
8.2.2. Market Size and Forecast, By Vector Type
8.2.3. Market Size and Forecast, By Workflow
8.2.4. Market Size and Forecast, By Application
8.2.5. Market Size and Forecast, By End User
8.2.6. Market Size and Forecast, By Country
8.2.7. U.S. Viral Vectors and Plasmid DNA Manufacturing Market
8.2.7.1. Market Size and Forecast, By Vector Type
8.2.7.2. Market Size and Forecast, By Workflow
8.2.7.3. Market Size and Forecast, By Application
8.2.7.4. Market Size and Forecast, By End User
8.2.8. Canada Viral Vectors and Plasmid DNA Manufacturing Market
8.2.8.1. Market Size and Forecast, By Vector Type
8.2.8.2. Market Size and Forecast, By Workflow
8.2.8.3. Market Size and Forecast, By Application
8.2.8.4. Market Size and Forecast, By End User
8.2.9. Mexico Viral Vectors and Plasmid DNA Manufacturing Market
8.2.9.1. Market Size and Forecast, By Vector Type
8.2.9.2. Market Size and Forecast, By Workflow
8.2.9.3. Market Size and Forecast, By Application
8.2.9.4. Market Size and Forecast, By End User
8.3. Europe
8.3.1. Key Market Trends and Opportunities
8.3.2. Market Size and Forecast, By Vector Type
8.3.3. Market Size and Forecast, By Workflow
8.3.4. Market Size and Forecast, By Application
8.3.5. Market Size and Forecast, By End User
8.3.6. Market Size and Forecast, By Country
8.3.7. Germany Viral Vectors and Plasmid DNA Manufacturing Market
8.3.7.1. Market Size and Forecast, By Vector Type
8.3.7.2. Market Size and Forecast, By Workflow
8.3.7.3. Market Size and Forecast, By Application
8.3.7.4. Market Size and Forecast, By End User
8.3.8. France Viral Vectors and Plasmid DNA Manufacturing Market
8.3.8.1. Market Size and Forecast, By Vector Type
8.3.8.2. Market Size and Forecast, By Workflow
8.3.8.3. Market Size and Forecast, By Application
8.3.8.4. Market Size and Forecast, By End User
8.3.9. UK Viral Vectors and Plasmid DNA Manufacturing Market
8.3.9.1. Market Size and Forecast, By Vector Type
8.3.9.2. Market Size and Forecast, By Workflow
8.3.9.3. Market Size and Forecast, By Application
8.3.9.4. Market Size and Forecast, By End User
8.3.10. Italy Viral Vectors and Plasmid DNA Manufacturing Market
8.3.10.1. Market Size and Forecast, By Vector Type
8.3.10.2. Market Size and Forecast, By Workflow
8.3.10.3. Market Size and Forecast, By Application
8.3.10.4. Market Size and Forecast, By End User
8.3.11. Spain Viral Vectors and Plasmid DNA Manufacturing Market
8.3.11.1. Market Size and Forecast, By Vector Type
8.3.11.2. Market Size and Forecast, By Workflow
8.3.11.3. Market Size and Forecast, By Application
8.3.11.4. Market Size and Forecast, By End User
8.3.12. Rest Of Europe Viral Vectors and Plasmid DNA Manufacturing Market
8.3.12.1. Market Size and Forecast, By Vector Type
8.3.12.2. Market Size and Forecast, By Workflow
8.3.12.3. Market Size and Forecast, By Application
8.3.12.4. Market Size and Forecast, By End User
8.4. Asia-Pacific
8.4.1. Key Market Trends and Opportunities
8.4.2. Market Size and Forecast, By Vector Type
8.4.3. Market Size and Forecast, By Workflow
8.4.4. Market Size and Forecast, By Application
8.4.5. Market Size and Forecast, By End User
8.4.6. Market Size and Forecast, By Country
8.4.7. Japan Viral Vectors and Plasmid DNA Manufacturing Market
8.4.7.1. Market Size and Forecast, By Vector Type
8.4.7.2. Market Size and Forecast, By Workflow
8.4.7.3. Market Size and Forecast, By Application
8.4.7.4. Market Size and Forecast, By End User
8.4.8. China Viral Vectors and Plasmid DNA Manufacturing Market
8.4.8.1. Market Size and Forecast, By Vector Type
8.4.8.2. Market Size and Forecast, By Workflow
8.4.8.3. Market Size and Forecast, By Application
8.4.8.4. Market Size and Forecast, By End User
8.4.9. Australia Viral Vectors and Plasmid DNA Manufacturing Market
8.4.9.1. Market Size and Forecast, By Vector Type
8.4.9.2. Market Size and Forecast, By Workflow
8.4.9.3. Market Size and Forecast, By Application
8.4.9.4. Market Size and Forecast, By End User
8.4.10. India Viral Vectors and Plasmid DNA Manufacturing Market
8.4.10.1. Market Size and Forecast, By Vector Type
8.4.10.2. Market Size and Forecast, By Workflow
8.4.10.3. Market Size and Forecast, By Application
8.4.10.4. Market Size and Forecast, By End User
8.4.11. South Korea Viral Vectors and Plasmid DNA Manufacturing Market
8.4.11.1. Market Size and Forecast, By Vector Type
8.4.11.2. Market Size and Forecast, By Workflow
8.4.11.3. Market Size and Forecast, By Application
8.4.11.4. Market Size and Forecast, By End User
8.4.12. Rest of Asia-Pacific Viral Vectors and Plasmid DNA Manufacturing Market
8.4.12.1. Market Size and Forecast, By Vector Type
8.4.12.2. Market Size and Forecast, By Workflow
8.4.12.3. Market Size and Forecast, By Application
8.4.12.4. Market Size and Forecast, By End User
8.5. LAMEA
8.5.1. Key Market Trends and Opportunities
8.5.2. Market Size and Forecast, By Vector Type
8.5.3. Market Size and Forecast, By Workflow
8.5.4. Market Size and Forecast, By Application
8.5.5. Market Size and Forecast, By End User
8.5.6. Market Size and Forecast, By Country
8.5.7. Brazil Viral Vectors and Plasmid DNA Manufacturing Market
8.5.7.1. Market Size and Forecast, By Vector Type
8.5.7.2. Market Size and Forecast, By Workflow
8.5.7.3. Market Size and Forecast, By Application
8.5.7.4. Market Size and Forecast, By End User
8.5.8. Saudi Arabia Viral Vectors and Plasmid DNA Manufacturing Market
8.5.8.1. Market Size and Forecast, By Vector Type
8.5.8.2. Market Size and Forecast, By Workflow
8.5.8.3. Market Size and Forecast, By Application
8.5.8.4. Market Size and Forecast, By End User
8.5.9. South Africa Viral Vectors and Plasmid DNA Manufacturing Market
8.5.9.1. Market Size and Forecast, By Vector Type
8.5.9.2. Market Size and Forecast, By Workflow
8.5.9.3. Market Size and Forecast, By Application
8.5.9.4. Market Size and Forecast, By End User
8.5.10. Rest of LAMEA Viral Vectors and Plasmid DNA Manufacturing Market
8.5.10.1. Market Size and Forecast, By Vector Type
8.5.10.2. Market Size and Forecast, By Workflow
8.5.10.3. Market Size and Forecast, By Application
8.5.10.4. Market Size and Forecast, By End User
CHAPTER 9: COMPETITIVE LANDSCAPE
9.1. Introduction
9.2. Top Winning Strategies
9.3. Product Mapping Of Top 10 Player
9.4. Competitive Dashboard
9.5. Competitive Heatmap
9.6. Top Player Positioning, 2023
CHAPTER 10: COMPANY PROFILES
10.1. Merck KGaA
10.1.1. Company Overview
10.1.2. Key Executives
10.1.3. Company Snapshot
10.1.4. Operating Business Segments
10.1.5. Product Portfolio
10.1.6. Business Performance
10.1.7. Key Strategic Moves and Developments
10.2. Lonza Group AG
10.2.1. Company Overview
10.2.2. Key Executives
10.2.3. Company Snapshot
10.2.4. Operating Business Segments
10.2.5. Product Portfolio
10.2.6. Business Performance
10.2.7. Key Strategic Moves and Developments
10.3. FUJIFILM Corporation
10.3.1. Company Overview
10.3.2. Key Executives
10.3.3. Company Snapshot
10.3.4. Operating Business Segments
10.3.5. Product Portfolio
10.3.6. Business Performance
10.3.7. Key Strategic Moves and Developments
10.4. Thermo Fisher Scientific
10.4.1. Company Overview
10.4.2. Key Executives
10.4.3. Company Snapshot
10.4.4. Operating Business Segments
10.4.5. Product Portfolio
10.4.6. Business Performance
10.4.7. Key Strategic Moves and Developments
10.5. Cobra Biologics
10.5.1. Company Overview
10.5.2. Key Executives
10.5.3. Company Snapshot
10.5.4. Operating Business Segments
10.5.5. Product Portfolio
10.5.6. Business Performance
10.5.7. Key Strategic Moves and Developments
10.6. Catalent Inc.
10.6.1. Company Overview
10.6.2. Key Executives
10.6.3. Company Snapshot
10.6.4. Operating Business Segments
10.6.5. Product Portfolio
10.6.6. Business Performance
10.6.7. Key Strategic Moves and Developments
10.7. WuXi Biologics.
10.7.1. Company Overview
10.7.2. Key Executives
10.7.3. Company Snapshot
10.7.4. Operating Business Segments
10.7.5. Product Portfolio
10.7.6. Business Performance
10.7.7. Key Strategic Moves and Developments
10.8. TakarBio Inc
10.8.1. Company Overview
10.8.2. Key Executives
10.8.3. Company Snapshot
10.8.4. Operating Business Segments
10.8.5. Product Portfolio
10.8.6. Business Performance
10.8.7. Key Strategic Moves and Developments
10.9. Waisman Biomanufacturing, LLC
10.9.1. Company Overview
10.9.2. Key Executives
10.9.3. Company Snapshot
10.9.4. Operating Business Segments
10.9.5. Product Portfolio
10.9.6. Business Performance
10.9.7. Key Strategic Moves and Developments
10.10. Genezen Laboratories
10.10.1. Company Overview
10.10.2. Key Executives
10.10.3. Company Snapshot
10.10.4. Operating Business Segments
10.10.5. Product Portfolio
10.10.6. Business Performance
10.10.7. Key Strategic Moves and Developments
LIST OF TABLES
TABLE 1. GLOBAL VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY VECTOR TYPE, 2024 - 2033 ($BILLION)
TABLE 2. VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET FOR ADENOVIRUS, BY REGION, 2024 - 2033 ($BILLION)
TABLE 3. VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET FOR RETROVIRUS, BY REGION, 2024 - 2033 ($BILLION)
TABLE 4. VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET FOR ADENO-ASSOCIATED VIRUS (AAV), BY REGION, 2024 - 2033 ($BILLION)
TABLE 5. VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET FOR LENTIVIRUS, BY REGION, 2024 - 2033 ($BILLION)
TABLE 6. VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET FOR PLASMIDS, BY REGION, 2024 - 2033 ($BILLION)
TABLE 7. VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET FOR OTHERS, BY REGION, 2024 - 2033 ($BILLION)
TABLE 8. GLOBAL VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY WORKFLOW, 2024 - 2033 ($BILLION)
TABLE 9. VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET FOR UPSTREAM MANUFACTURING, BY REGION, 2024 - 2033 ($BILLION)
TABLE 10. VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET FOR DOWNSTREAM MANUFACTURING, BY REGION, 2024 - 2033 ($BILLION)
TABLE 11. GLOBAL VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY APPLICATION, 2024 - 2033 ($BILLION)
TABLE 12. VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET FOR ANTISENSE RNAI THERAPY, BY REGION, 2024 - 2033 ($BILLION)
TABLE 13. VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET FOR ANTISENSE RNAI THERAPY, BY REGION, 2024 - 2033 ($BILLION)
TABLE 14. VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET FOR CELL THERAPY, BY REGION, 2024 - 2033 ($BILLION)
TABLE 15. VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET FOR VACCINOLOGY, BY REGION, 2024 - 2033 ($BILLION)
TABLE 16. VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET FOR RESEARCH APPLICATIONS, BY REGION, 2024 - 2033 ($BILLION)
TABLE 17. GLOBAL VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY END USER, 2024 - 2033 ($BILLION)
TABLE 18. VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET FOR PHARMACEUTICAL BIOPHARMACEUTICAL COMPANIES, BY REGION, 2024 - 2033 ($BILLION)
TABLE 19. VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET FOR RESEARCH INSTITUTES, BY REGION, 2024 - 2033 ($BILLION)
TABLE 20. VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY REGION, 2024 - 2033 ($BILLION)
TABLE 21. NORTH AMERICA VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY COUNTRY, 2024 - 2033 ($BILLION)
TABLE 22. NORTH AMERICA VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY VECTOR TYPE, 2024 - 2033 ($BILLION)
TABLE 23. NORTH AMERICA VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY WORKFLOW, 2024 - 2033 ($BILLION)
TABLE 24. NORTH AMERICA VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY APPLICATION, 2024 - 2033 ($BILLION)
TABLE 25. NORTH AMERICA VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY END USER, 2024 - 2033 ($BILLION)
TABLE 26. U.S. VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY VECTOR TYPE, 2024 - 2033 ($BILLION)
TABLE 27. U.S. VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY WORKFLOW, 2024 - 2033 ($BILLION)
TABLE 28. U.S. VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY APPLICATION, 2024 - 2033 ($BILLION)
TABLE 29. U.S. VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY END USER, 2024 - 2033 ($BILLION)
TABLE 30. CANADA VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY VECTOR TYPE, 2024 - 2033 ($BILLION)
TABLE 31. CANADA VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY WORKFLOW, 2024 - 2033 ($BILLION)
TABLE 32. CANADA VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY APPLICATION, 2024 - 2033 ($BILLION)
TABLE 33. CANADA VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY END USER, 2024 - 2033 ($BILLION)
TABLE 34. MEXICO VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY VECTOR TYPE, 2024 - 2033 ($BILLION)
TABLE 35. MEXICO VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY WORKFLOW, 2024 - 2033 ($BILLION)
TABLE 36. MEXICO VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY APPLICATION, 2024 - 2033 ($BILLION)
TABLE 37. MEXICO VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY END USER, 2024 - 2033 ($BILLION)
TABLE 38. EUROPE VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY COUNTRY, 2024 - 2033 ($BILLION)
TABLE 39. EUROPE VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY VECTOR TYPE, 2024 - 2033 ($BILLION)
TABLE 40. EUROPE VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY WORKFLOW, 2024 - 2033 ($BILLION)
TABLE 41. EUROPE VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY APPLICATION, 2024 - 2033 ($BILLION)
TABLE 42. EUROPE VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY END USER, 2024 - 2033 ($BILLION)
TABLE 43. GERMANY VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY VECTOR TYPE, 2024 - 2033 ($BILLION)
TABLE 44. GERMANY VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY WORKFLOW, 2024 - 2033 ($BILLION)
TABLE 45. GERMANY VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY APPLICATION, 2024 - 2033 ($BILLION)
TABLE 46. GERMANY VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY END USER, 2024 - 2033 ($BILLION)
TABLE 47. FRANCE VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY VECTOR TYPE, 2024 - 2033 ($BILLION)
TABLE 48. FRANCE VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY WORKFLOW, 2024 - 2033 ($BILLION)
TABLE 49. FRANCE VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY APPLICATION, 2024 - 2033 ($BILLION)
TABLE 50. FRANCE VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY END USER, 2024 - 2033 ($BILLION)
TABLE 51. UK VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY VECTOR TYPE, 2024 - 2033 ($BILLION)
TABLE 52. UK VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY WORKFLOW, 2024 - 2033 ($BILLION)
TABLE 53. UK VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY APPLICATION, 2024 - 2033 ($BILLION)
TABLE 54. UK VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY END USER, 2024 - 2033 ($BILLION)
TABLE 55. ITALY VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY VECTOR TYPE, 2024 - 2033 ($BILLION)
TABLE 56. ITALY VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY WORKFLOW, 2024 - 2033 ($BILLION)
TABLE 57. ITALY VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY APPLICATION, 2024 - 2033 ($BILLION)
TABLE 58. ITALY VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY END USER, 2024 - 2033 ($BILLION)
TABLE 59. SPAIN VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY VECTOR TYPE, 2024 - 2033 ($BILLION)
TABLE 60. SPAIN VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY WORKFLOW, 2024 - 2033 ($BILLION)
TABLE 61. SPAIN VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY APPLICATION, 2024 - 2033 ($BILLION)
TABLE 62. SPAIN VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY END USER, 2024 - 2033 ($BILLION)
TABLE 63. REST OF EUROPE VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY VECTOR TYPE, 2024 - 2033 ($BILLION)
TABLE 64. REST OF EUROPE VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY WORKFLOW, 2024 - 2033 ($BILLION)
TABLE 65. REST OF EUROPE VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY APPLICATION, 2024 - 2033 ($BILLION)
TABLE 66. REST OF EUROPE VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY END USER, 2024 - 2033 ($BILLION)
TABLE 67. ASIA-PACIFIC VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY COUNTRY, 2024 - 2033 ($BILLION)
TABLE 68. ASIA-PACIFIC VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY VECTOR TYPE, 2024 - 2033 ($BILLION)
TABLE 69. ASIA-PACIFIC VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY WORKFLOW, 2024 - 2033 ($BILLION)
TABLE 70. ASIA-PACIFIC VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY APPLICATION, 2024 - 2033 ($BILLION)
TABLE 71. ASIA-PACIFIC VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY END USER, 2024 - 2033 ($BILLION)
TABLE 72. JAPAN VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY VECTOR TYPE, 2024 - 2033 ($BILLION)
TABLE 73. JAPAN VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY WORKFLOW, 2024 - 2033 ($BILLION)
TABLE 74. JAPAN VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY APPLICATION, 2024 - 2033 ($BILLION)
TABLE 75. JAPAN VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY END USER, 2024 - 2033 ($BILLION)
TABLE 76. CHINA VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY VECTOR TYPE, 2024 - 2033 ($BILLION)
TABLE 77. CHINA VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY WORKFLOW, 2024 - 2033 ($BILLION)
TABLE 78. CHINA VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY APPLICATION, 2024 - 2033 ($BILLION)
TABLE 79. CHINA VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY END USER, 2024 - 2033 ($BILLION)
TABLE 80. AUSTRALIA VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY VECTOR TYPE, 2024 - 2033 ($BILLION)
TABLE 81. AUSTRALIA VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY WORKFLOW, 2024 - 2033 ($BILLION)
TABLE 82. AUSTRALIA VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY APPLICATION, 2024 - 2033 ($BILLION)
TABLE 83. AUSTRALIA VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY END USER, 2024 - 2033 ($BILLION)
TABLE 84. INDIA VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY VECTOR TYPE, 2024 - 2033 ($BILLION)
TABLE 85. INDIA VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY WORKFLOW, 2024 - 2033 ($BILLION)
TABLE 86. INDIA VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY APPLICATION, 2024 - 2033 ($BILLION)
TABLE 87. INDIA VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY END USER, 2024 - 2033 ($BILLION)
TABLE 88. SOUTH KOREA VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY VECTOR TYPE, 2024 - 2033 ($BILLION)
TABLE 89. SOUTH KOREA VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY WORKFLOW, 2024 - 2033 ($BILLION)
TABLE 90. SOUTH KOREA VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY APPLICATION, 2024 - 2033 ($BILLION)
TABLE 91. SOUTH KOREA VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY END USER, 2024 - 2033 ($BILLION)
TABLE 92. REST OF ASIA-PACIFIC VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY VECTOR TYPE, 2024 - 2033 ($BILLION)
TABLE 93. REST OF ASIA-PACIFIC VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY WORKFLOW, 2024 - 2033 ($BILLION)
TABLE 94. REST OF ASIA-PACIFIC VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY APPLICATION, 2024 - 2033 ($BILLION)
TABLE 95. REST OF ASIA-PACIFIC VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY END USER, 2024 - 2033 ($BILLION)
TABLE 96. LAMEA VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY COUNTRY, 2024 - 2033 ($BILLION)
TABLE 97. LAMEA VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY VECTOR TYPE, 2024 - 2033 ($BILLION)
TABLE 98. LAMEA VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY WORKFLOW, 2024 - 2033 ($BILLION)
TABLE 99. LAMEA VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY APPLICATION, 2024 - 2033 ($BILLION)
TABLE 100. LAMEA VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY END USER, 2024 - 2033 ($BILLION)
TABLE 101. BRAZIL VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY VECTOR TYPE, 2024 - 2033 ($BILLION)
TABLE 102. BRAZIL VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY WORKFLOW, 2024 - 2033 ($BILLION)
TABLE 103. BRAZIL VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY APPLICATION, 2024 - 2033 ($BILLION)
TABLE 104. BRAZIL VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY END USER, 2024 - 2033 ($BILLION)
TABLE 105. SAUDI ARABIA VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY VECTOR TYPE, 2024 - 2033 ($BILLION)
TABLE 106. SAUDI ARABIA VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY WORKFLOW, 2024 - 2033 ($BILLION)
TABLE 107. SAUDI ARABIA VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY APPLICATION, 2024 - 2033 ($BILLION)
TABLE 108. SAUDI ARABIA VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY END USER, 2024 - 2033 ($BILLION)
TABLE 109. SOUTH AFRICA VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY VECTOR TYPE, 2024 - 2033 ($BILLION)
TABLE 110. SOUTH AFRICA VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY WORKFLOW, 2024 - 2033 ($BILLION)
TABLE 111. SOUTH AFRICA VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY APPLICATION, 2024 - 2033 ($BILLION)
TABLE 112. SOUTH AFRICA VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY END USER, 2024 - 2033 ($BILLION)
TABLE 113. REST OF LAMEA VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY VECTOR TYPE, 2024 - 2033 ($BILLION)
TABLE 114. REST OF LAMEA VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY WORKFLOW, 2024 - 2033 ($BILLION)
TABLE 115. REST OF LAMEA VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY APPLICATION, 2024 - 2033 ($BILLION)
TABLE 116. REST OF LAMEA VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY END USER, 2024 - 2033 ($BILLION)
TABLE 117. MERCK KGAA: KEY EXECUTIVES
TABLE 118. MERCK KGAA: COMPANY SNAPSHOT
TABLE 119. MERCK KGAA: OPERATING SEGMENTS
TABLE 120. MERCK KGAA: PRODUCT PORTFOLIO
TABLE 121. MERCK KGAA: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 122. LONZA GROUP AG: KEY EXECUTIVES
TABLE 123. LONZA GROUP AG: COMPANY SNAPSHOT
TABLE 124. LONZA GROUP AG: OPERATING SEGMENTS
TABLE 125. LONZA GROUP AG: PRODUCT PORTFOLIO
TABLE 126. LONZA GROUP AG: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 127. FUJIFILM CORPORATION: KEY EXECUTIVES
TABLE 128. FUJIFILM CORPORATION: COMPANY SNAPSHOT
TABLE 129. FUJIFILM CORPORATION: OPERATING SEGMENTS
TABLE 130. FUJIFILM CORPORATION: PRODUCT PORTFOLIO
TABLE 131. FUJIFILM CORPORATION: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 132. THERMO FISHER SCIENTIFIC: KEY EXECUTIVES
TABLE 133. THERMO FISHER SCIENTIFIC: COMPANY SNAPSHOT
TABLE 134. THERMO FISHER SCIENTIFIC: OPERATING SEGMENTS
TABLE 135. THERMO FISHER SCIENTIFIC: PRODUCT PORTFOLIO
TABLE 136. THERMO FISHER SCIENTIFIC: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 137. COBRA BIOLOGICS: KEY EXECUTIVES
TABLE 138. COBRA BIOLOGICS: COMPANY SNAPSHOT
TABLE 139. COBRA BIOLOGICS: OPERATING SEGMENTS
TABLE 140. COBRA BIOLOGICS: PRODUCT PORTFOLIO
TABLE 141. COBRA BIOLOGICS: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 142. CATALENT INC.: KEY EXECUTIVES
TABLE 143. CATALENT INC.: COMPANY SNAPSHOT
TABLE 144. CATALENT INC.: OPERATING SEGMENTS
TABLE 145. CATALENT INC.: PRODUCT PORTFOLIO
TABLE 146. CATALENT INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 147. WUXI BIOLOGICS.: KEY EXECUTIVES
TABLE 148. WUXI BIOLOGICS.: COMPANY SNAPSHOT
TABLE 149. WUXI BIOLOGICS.: OPERATING SEGMENTS
TABLE 150. WUXI BIOLOGICS.: PRODUCT PORTFOLIO
TABLE 151. WUXI BIOLOGICS.: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 152. TAKARBIO INC: KEY EXECUTIVES
TABLE 153. TAKARBIO INC: COMPANY SNAPSHOT
TABLE 154. TAKARBIO INC: OPERATING SEGMENTS
TABLE 155. TAKARBIO INC: PRODUCT PORTFOLIO
TABLE 156. TAKARBIO INC: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 157. WAISMAN BIOMANUFACTURING, LLC: KEY EXECUTIVES
TABLE 158. WAISMAN BIOMANUFACTURING, LLC: COMPANY SNAPSHOT
TABLE 159. WAISMAN BIOMANUFACTURING, LLC: OPERATING SEGMENTS
TABLE 160. WAISMAN BIOMANUFACTURING, LLC: PRODUCT PORTFOLIO
TABLE 161. WAISMAN BIOMANUFACTURING, LLC: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 162. GENEZEN LABORATORIES: KEY EXECUTIVES
TABLE 163. GENEZEN LABORATORIES: COMPANY SNAPSHOT
TABLE 164. GENEZEN LABORATORIES: OPERATING SEGMENTS
TABLE 165. GENEZEN LABORATORIES: PRODUCT PORTFOLIO
TABLE 166. GENEZEN LABORATORIES: KEY STRATEGIC MOVES AND DEVELOPMENTS
LIST OF FIGURES
FIGURE 1. GLOBAL VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, 2024 - 2033
FIGURE 2. SEGMENTATION OF VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, 2024 - 2033
FIGURE 3. TOP INVESTMENT POCKET IN VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET
FIGURE 4. MODERATE BARGAINING POWER OF BUYERS
FIGURE 5. MODERATE BARGAINING POWER OF SUPPLIERS
FIGURE 6. MODERATE THREAT OF NEW ENTRANTS
FIGURE 7. LOW THREAT OF SUBSTITUTION
FIGURE 8. HIGH COMPETITIVE RIVALRY
FIGURE 9. OPPORTUNITIES, RESTRAINTS AND DRIVERS: GLOBALVIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET
FIGURE 10. GLOBAL VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET SEGMENTATION, BY VECTOR TYPE
FIGURE 11. VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET FOR ADENOVIRUS, BY COUNTRY, 2024 - 2033 ($BILLION)
FIGURE 12. VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET FOR RETROVIRUS, BY COUNTRY, 2024 - 2033 ($BILLION)
FIGURE 13. VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET FOR ADENO-ASSOCIATED VIRUS (AAV), BY COUNTRY, 2024 - 2033 ($BILLION)
FIGURE 14. VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET FOR LENTIVIRUS, BY COUNTRY, 2024 - 2033 ($BILLION)
FIGURE 15. VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET FOR PLASMIDS, BY COUNTRY, 2024 - 2033 ($BILLION)
FIGURE 16. VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET FOR OTHERS, BY COUNTRY, 2024 - 2033 ($BILLION)
FIGURE 17. GLOBAL VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET SEGMENTATION, BY WORKFLOW
FIGURE 18. VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET FOR UPSTREAM MANUFACTURING, BY COUNTRY, 2024 - 2033 ($BILLION)
FIGURE 19. VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET FOR DOWNSTREAM MANUFACTURING, BY COUNTRY, 2024 - 2033 ($BILLION)
FIGURE 20. GLOBAL VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET SEGMENTATION, BY APPLICATION
FIGURE 21. VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET FOR ANTISENSE RNAI THERAPY, BY COUNTRY, 2024 - 2033 ($BILLION)
FIGURE 22. VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET FOR ANTISENSE RNAI THERAPY, BY COUNTRY, 2024 - 2033 ($BILLION)
FIGURE 23. VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET FOR CELL THERAPY, BY COUNTRY, 2024 - 2033 ($BILLION)
FIGURE 24. VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET FOR VACCINOLOGY, BY COUNTRY, 2024 - 2033 ($BILLION)
FIGURE 25. VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET FOR RESEARCH APPLICATIONS, BY COUNTRY, 2024 - 2033 ($BILLION)
FIGURE 26. GLOBAL VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET SEGMENTATION, BY END USER
FIGURE 27. VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET FOR PHARMACEUTICAL BIOPHARMACEUTICAL COMPANIES, BY COUNTRY, 2024 - 2033 ($BILLION)
FIGURE 28. VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET FOR RESEARCH INSTITUTES, BY COUNTRY, 2024 - 2033 ($BILLION)
FIGURE 29. TOP WINNING STRATEGIES, BY YEAR, 2021-2023*
FIGURE 30. TOP WINNING STRATEGIES, BY DEVELOPMENT, 2021-2023*
FIGURE 31. TOP WINNING STRATEGIES, BY COMPANY, 2021-2023*
FIGURE 32. PRODUCT MAPPING OF TOP 10 PLAYERS
FIGURE 33. COMPETITIVE DASHBOARD
FIGURE 34. COMPETITIVE HEATMAP: VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET
FIGURE 35. TOP PLAYER POSITIONING, 2023
FIGURE 36. MERCK KGAA: NET SALES, 2021-2023 ($BILLION)
FIGURE 37. MERCK KGAA: REVENUE SHARE, BY SEGMENT, 2023 (%)
FIGURE 38. MERCK KGAA: REVENUE SHARE, BY REGION, 2023 (%)
FIGURE 39. LONZA GROUP AG: NET SALES, 2021-2023 ($BILLION)
FIGURE 40. LONZA GROUP AG: REVENUE SHARE, BY SEGMENT, 2023 (%)
FIGURE 41. LONZA GROUP AG: REVENUE SHARE, BY REGION, 2023 (%)
FIGURE 42. FUJIFILM CORPORATION: NET SALES, 2021-2023 ($BILLION)
FIGURE 43. FUJIFILM CORPORATION: REVENUE SHARE, BY SEGMENT, 2023 (%)
FIGURE 44. FUJIFILM CORPORATION: REVENUE SHARE, BY REGION, 2023 (%)
FIGURE 45. THERMO FISHER SCIENTIFIC: NET SALES, 2021-2023 ($BILLION)
FIGURE 46. THERMO FISHER SCIENTIFIC: REVENUE SHARE, BY SEGMENT, 2023 (%)
FIGURE 47. THERMO FISHER SCIENTIFIC: REVENUE SHARE, BY REGION, 2023 (%)
FIGURE 48. COBRA BIOLOGICS: NET SALES, 2021-2023 ($BILLION)
FIGURE 49. COBRA BIOLOGICS: REVENUE SHARE, BY SEGMENT, 2023 (%)
FIGURE 50. COBRA BIOLOGICS: REVENUE SHARE, BY REGION, 2023 (%)
FIGURE 51. CATALENT INC.: NET SALES, 2021-2023 ($BILLION)
FIGURE 52. CATALENT INC.: REVENUE SHARE, BY SEGMENT, 2023 (%)
FIGURE 53. CATALENT INC.: REVENUE SHARE, BY REGION, 2023 (%)
FIGURE 54. WUXI BIOLOGICS.: NET SALES, 2021-2023 ($BILLION)
FIGURE 55. WUXI BIOLOGICS.: REVENUE SHARE, BY SEGMENT, 2023 (%)
FIGURE 56. WUXI BIOLOGICS.: REVENUE SHARE, BY REGION, 2023 (%)
FIGURE 57. TAKARBIO INC: NET SALES, 2021-2023 ($BILLION)
FIGURE 58. TAKARBIO INC: REVENUE SHARE, BY SEGMENT, 2023 (%)
FIGURE 59. TAKARBIO INC: REVENUE SHARE, BY REGION, 2023 (%)
FIGURE 60. WAISMAN BIOMANUFACTURING, LLC: NET SALES, 2021-2023 ($BILLION)
FIGURE 61. WAISMAN BIOMANUFACTURING, LLC: REVENUE SHARE, BY SEGMENT, 2023 (%)
FIGURE 62. WAISMAN BIOMANUFACTURING, LLC: REVENUE SHARE, BY REGION, 2023 (%)
FIGURE 63. GENEZEN LABORATORIES: NET SALES, 2021-2023 ($BILLION)
FIGURE 64. GENEZEN LABORATORIES: REVENUE SHARE, BY SEGMENT, 2023 (%)
FIGURE 65. GENEZEN LABORATORIES: REVENUE SHARE, BY REGION, 2023 (%)
